Limits...
Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission.

Li Q, Li W, Wang L, Wang W, Niu S, Bi X, Wang H, Zhang Y - PLoS ONE (2015)

Bottom Line: Locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) were compared between patients with or without radiotherapy.The 10-year LRFS, DFS, OS and DMFS were 100% and 81.4% (p = 0.028), 91.7% and 77.1% (p = 0.14), 91.7% and 77.8% (p = 0.67), 91.7% and 78.0% (p = 0.42) for patients with or without radiotherapy.Radiotherapy is associated with improved locoregional control of patients with early stage primary gastric DLBCL, who have achieved complete remission following at least four cycles of chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China.

ABSTRACT

Background: To investigate the effects of consolidation radiation in patients with stage IE-IIE, non-bulky primary gastric diffuse large B-cell lymphoma (DLBCL).

Methods: A cohort consisted of 71 consecutive patients with stage IE-IIE, non-bulky primary gastric DLBCL was retrospectively analyzed. All of them had been in complete remission after receiving at least four cycles of chemotherapy, containing rituximab or not. Consolidation radiation was delivered thereafter in 28 patients while other 43 received clinical observation only. Locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) were compared between patients with or without radiotherapy.

Results: The 10-year LRFS, DFS, OS and DMFS were 100% and 81.4% (p = 0.028), 91.7% and 77.1% (p = 0.14), 91.7% and 77.8% (p = 0.67), 91.7% and 78.0% (p = 0.42) for patients with or without radiotherapy.

Conclusions: Radiotherapy is associated with improved locoregional control of patients with early stage primary gastric DLBCL, who have achieved complete remission following at least four cycles of chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Distant metastasis-free survival of patients with or without radiotherapy.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508098&req=5

pone.0133469.g004: Distant metastasis-free survival of patients with or without radiotherapy.

Mentions: The 10-year LRFS, DFS, OS and DMFS for all patients were 88.6%, 78.0%, 81.2% and 82.3%. In RT and non-RT group, they were 100% and 81.4% (p = 0.028, Fig 1), 91.7% and 77.1% (p = 0.14, Fig 2), 91.7% and 77.8% (p = 0.67, Fig 3), 91.7% and 78.0% (p = 0.42, Fig 4). When analyzed by univariate, DFS was affected by stage (5-year DFS: IE vs IIE: 94.1% vs 60.4%, p = 0.012) and IPI (5-year DFS: 0 vs 1 vs 2 vs 3: 84.6% vs 86.6% vs 87.5% vs 0%, p = 0.017). DMFS was affected by IPI (5-year DMFS: 0 vs 1 vs 2 vs 3: 90.5% vs 90.2% vs 87.5% vs 0%, p = 0.002). OS was affected by stage (5-year OS: IE vs. IIE: 100% vs 62.3%, p = 0.004) and IPI (5-year OS: 0 vs 1 vs 2 vs 3: 96.8% vs 73.0% vs 87.5% vs 0%, p = 0.001). None of other clinico-pathologic factors, except for radiotherapy, was statistically related to LRFS (5-year LRFS: RT vs non-RT: 100% vs. 81.4%, p = 0.028, Table 2). On multivariate analysis, stage was identified as an independent prognostic factors for DFS, with hazard ratio 0.18 (95% confidence interval: 0.036–0.897, p = 0.036). Unfortunately, the numbers of events of interest for LRFS, OS and DMFS are not enough to allow multivariate analysis in the study.


Consolidation Radiotherapy in Stage IE- IIE, Non-Bulky Primary Gastric Diffuse Large B-Cell Lymphoma with Post-Chemotherapy Complete Remission.

Li Q, Li W, Wang L, Wang W, Niu S, Bi X, Wang H, Zhang Y - PLoS ONE (2015)

Distant metastasis-free survival of patients with or without radiotherapy.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508098&req=5

pone.0133469.g004: Distant metastasis-free survival of patients with or without radiotherapy.
Mentions: The 10-year LRFS, DFS, OS and DMFS for all patients were 88.6%, 78.0%, 81.2% and 82.3%. In RT and non-RT group, they were 100% and 81.4% (p = 0.028, Fig 1), 91.7% and 77.1% (p = 0.14, Fig 2), 91.7% and 77.8% (p = 0.67, Fig 3), 91.7% and 78.0% (p = 0.42, Fig 4). When analyzed by univariate, DFS was affected by stage (5-year DFS: IE vs IIE: 94.1% vs 60.4%, p = 0.012) and IPI (5-year DFS: 0 vs 1 vs 2 vs 3: 84.6% vs 86.6% vs 87.5% vs 0%, p = 0.017). DMFS was affected by IPI (5-year DMFS: 0 vs 1 vs 2 vs 3: 90.5% vs 90.2% vs 87.5% vs 0%, p = 0.002). OS was affected by stage (5-year OS: IE vs. IIE: 100% vs 62.3%, p = 0.004) and IPI (5-year OS: 0 vs 1 vs 2 vs 3: 96.8% vs 73.0% vs 87.5% vs 0%, p = 0.001). None of other clinico-pathologic factors, except for radiotherapy, was statistically related to LRFS (5-year LRFS: RT vs non-RT: 100% vs. 81.4%, p = 0.028, Table 2). On multivariate analysis, stage was identified as an independent prognostic factors for DFS, with hazard ratio 0.18 (95% confidence interval: 0.036–0.897, p = 0.036). Unfortunately, the numbers of events of interest for LRFS, OS and DMFS are not enough to allow multivariate analysis in the study.

Bottom Line: Locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) were compared between patients with or without radiotherapy.The 10-year LRFS, DFS, OS and DMFS were 100% and 81.4% (p = 0.028), 91.7% and 77.1% (p = 0.14), 91.7% and 77.8% (p = 0.67), 91.7% and 78.0% (p = 0.42) for patients with or without radiotherapy.Radiotherapy is associated with improved locoregional control of patients with early stage primary gastric DLBCL, who have achieved complete remission following at least four cycles of chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China.

ABSTRACT

Background: To investigate the effects of consolidation radiation in patients with stage IE-IIE, non-bulky primary gastric diffuse large B-cell lymphoma (DLBCL).

Methods: A cohort consisted of 71 consecutive patients with stage IE-IIE, non-bulky primary gastric DLBCL was retrospectively analyzed. All of them had been in complete remission after receiving at least four cycles of chemotherapy, containing rituximab or not. Consolidation radiation was delivered thereafter in 28 patients while other 43 received clinical observation only. Locoregional relapse-free survival (LRFS), disease-free survival (DFS), overall survival (OS) and distant metastasis-free survival (DMFS) were compared between patients with or without radiotherapy.

Results: The 10-year LRFS, DFS, OS and DMFS were 100% and 81.4% (p = 0.028), 91.7% and 77.1% (p = 0.14), 91.7% and 77.8% (p = 0.67), 91.7% and 78.0% (p = 0.42) for patients with or without radiotherapy.

Conclusions: Radiotherapy is associated with improved locoregional control of patients with early stage primary gastric DLBCL, who have achieved complete remission following at least four cycles of chemotherapy.

No MeSH data available.


Related in: MedlinePlus